slide1
Download
Skip this Video
Download Presentation
Prepared by J. Mabbutt & C. Maynard NaMO September 2008

Loading in 2 Seconds...

play fullscreen
1 / 26

Prepared by J. Mabbutt & C. Maynard NaMO September 2008 - PowerPoint PPT Presentation


  • 283 Views
  • Uploaded on

8.1: Managing Opiate and Psychostimulant Withdrawal. Prepared by J. Mabbutt & C. Maynard NaMO September 2008. 8.4: Managing opiate and psychostimulant withdrawal – Objectives.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Prepared by J. Mabbutt & C. Maynard NaMO September 2008' - DoraAna


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
slide1
8.1: Managing Opiate and Psychostimulant

Withdrawal

Prepared byJ. Mabbutt & C. MaynardNaMO

September 2008

slide2
8.4: Managing opiate and psychostimulant withdrawal – Objectives

1. During the session nurses & midwives will learn how to identify, assess and manage a patient in opiate and psychostimulant withdrawal

2. By the end of the session nurses & midwives will have an understanding or use of the opiate withdrawal scales

3. At the end the session, nurses & midwives will have a basic understanding & knowledge to safely & effectively identify, monitor & manage opiate & psychostimulant withdrawal

slide3
8.1: Managing drug withdrawal

This presentation gives general guidelines for managing withdrawal. Refer to Section 9 for specific details of withdrawal symptoms and management for the most commonly used substances

For further information, refer to the New South Wales Drug and Alcohol Withdrawal Clinical Practice Guidelines (2007) http://www.health.nsw.gov.au/policies/gl/2008/GL2008_011.html

slide4
8:1 Indications and guidelinesOpioid Withdrawal – Onset & Duration of withdrawal (1)
  • Heroin is a relatively short-acting drug
  • Symptoms of withdrawal usually commence 6-24 hours after the last dose, reach a peak at 24-48 hours, & resolve after 5-10 days
  • Methadone or other long-acting opioids withdrawal usually commences 36-48 hours after the last dose
  • The peak severity of methadone withdrawal tends to be lower than for heroin withdrawal, but withdrawal may be more prolonged, lasting 3-6 weeks
slide5
8:1 Indications and guidelinesOpioid Withdrawal – Onset & Duration of withdrawal (2)
  • Buprenorphine withdrawal is similar to other opioids but is generally milder than withdrawal from methadone or heroin because of its slow dissociation from the opioid receptors
  • Symptoms commence generally within 3–5 days of the last dose and can last for several weeks
slide6
8:1 Indications and guidelinesOpioid Withdrawal – Onset & Duration of withdrawal (3)
  • Following acute withdrawal, protracted, low-grade symptoms of discomfort (psychological and physical) may last many months
  • Table 9.5 shows times of appearance of withdrawal syndrome in dependent opioid users
slide8
8:1 Indications and guidelinesWithdrawal – Onset & Duration of withdrawal (4)
  • The opioid withdrawal syndrome can be very uncomfortable & distressing, but not life-threatening unless there is a severe underlying disease
  • Patients may have a low tolerance to pain due to the effect of long-term opioid use & this needs to be acknowledged & treated effectively
  • The following Graph – Figure 9.2 shows the progress of the acute phase of opioid withdrawal after last dose
slide9
8:1 Figure 9.2: Progress of the acute phase of opioid withdrawal

Adapted from NSW Health Withdrawal Clinical Practice Guidelines (2007)

slide11
8:1 Indications and guidelines Pharmacological treatment for opioid withdrawal
  • The medical officer or drug & alcohol nurse practitioner may prescribe the preferred pharmacological option for opioid withdrawal:
  • Buprenorphine
  • Symptomatic medications
slide12
8:1 Buprenorphine Treatment for opioid withdrawal – Hospital Setting (1)
  • Buprenorphine is well suited in the hospital setting as it alleviates symptoms of withdrawal without significantly prolonging the duration of symptoms
  • There should be some ability to tailor doses to degree of withdrawal as assessed by the Clinical Opiate Withdrawal Scale (COWS) (see Appendix 4)
  • Buprenorphine should not be commenced until objective withdrawal is present (COWS score greater than eight) to reduce likelihood of precipitating withdrawal
slide13
8:1 Buprenorphine Treatment for opioid withdrawal – Hospital Setting (2)
  • Commencing buprenorphine before the patient has withdrawal signs can cause them to go into a a rapid withdrawal syndrome & cause great distress to them
  • Using the COWS as noted can help reduce this risk
  • Buprenorphine will bind tighter to the opiate receptor sites than the opiate drug (e.g. heroin/methadone) the person is normally on.
  • This will throw the opiate off the receptor site & put the patient into to a precipitated (severe) withdrawal
slide15
8:1 Table 9.8 Symptomatic treatment

Note: Caution is recommended in exceeding stated duration of benzodiazepine use to avoid substituting for heroin dependence.

Duration of treatment may need to be longer than stated above for withdrawal from long-acting opioid (e.g. methadone, Kapanol etc).

slide16
8:1 Table 9.8 Symptomatic treatment

Note: Caution is recommended in exceeding stated duration of benzodiazepine use to avoid substituting for heroin dependence.

Duration of treatment may need to be longer than stated above for withdrawal from long-acting opioid (e.g. methadone, Kapanol etc).

slide17
8:1 Indications and guidelinesWithdrawal – Psychostimulant withdrawal – Case Study
  • Present relevant case study for psychostimulant intoxication or other drug withdrawal from Guidelines CD Rom Section 01
  • Discuss each section in small groups or as a large group and feedback
slide18
8:1 Indications and guidelinesManaging psychostimulant withdrawal (1)
  • Psychostimulants are: Amphetamines, cocaine & ecstasy
  • Amphetamines are: amphetamines (speed), methamphetamines (‘ice’) & dexamphetamine (Ritalin),
  • Repeated and prolonged use of psychostimulants leads to marked tolerance, neuro-adaption & dependence, & withdrawal on cessation
  • Withdrawal from cocaine or amphetamines is not life-threatening
  • Depression resulting from withdrawal can lead to suicidal ideation, self-harm and possibly death
slide19
8:1 Amphetamines
  • Three forms of Amphetamines
  • Powder, Base & Crystal
  • meth/amphetamine powder approx 10% pure
  • meth /amphetamine base approx 20% pure
  • methamphetamine crystal–‘ice’ approx 80% pure

Powder

Base

Crystal

slide20
8:1 Indications and guidelinesManaging psychostimulant withdrawal (2)
  • Suicidal ideation should be managed as per hospital policy & NSW Department of Health Policy Directive No. PD2005_121 Suicidal Behaviour – Management of Patients with Possible Suicidal Behaviour athttp://www.health.nsw.gov.au/policies/PD/2005/PD2005_121.html
  • Also refer to the Framework for Suicide Risk Assessment and Management for NSW Health Staff athttp://www.health.nsw.gov.au/pubs/2005/suicide_risk.html
  • See also: NSW Health 2006: Psychostimulant Users – Clinical Guidelines for Assessment and Management: GL2006_001:
slide21
8:1 Indications and guidelinesManaging psychostimulant withdrawal (3)

Withdrawal is characterised by three phases:

  • Crash
  • Withdrawal
  • Extinction
  • Table 9.12 shows the phases of amphetamine & cocaine withdrawal
slide25
8:1 Indications and guidelinesManaging psychostimulant withdrawal – Monitoring
  • Four-hourly monitoring is recommended as nurses/midwives need to be aware of changing signs & symptoms that the patient may present with as they pass through the crash & withdrawal phases
  • Mood & energy levels may fluctuate e.g. a patient may initially present with a low mood and psychomotor retardation & then swing towards being restless & agitated later the same day
  • Assess for underlying mental health problems as these may have been masked during the crash phase but become evident later in the withdrawal period
  • Withdrawal scales have not been routinely used in clinical practice
slide26
8:1 Indications and guidelinesPharmacological treatment
  • To date, no broadly effective pharmacological therapy has been identified

However, symptomatic medication may be beneficial, for example:

  • Benzodiazepines for anxiety, agitation, insomnia & aggressive outbursts – not be used for more than two weeks without review
  • Antipsychotic medication for psychotic symptoms (delusions, hallucinations etc)
  • Antidepressants for symptoms of depression that persist after stimulant withdrawal
ad